| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8485511 | Vaccine | 2018 | 7 Pages |
Abstract
The cost-effectiveness ratios we estimated are not so favorable as to make a strong economic case for recommending expanding male vaccination, yet are not so unfavorable as to preclude consideration of expanding male vaccination. The wide range of plausible results we obtained may underestimate the true degree of uncertainty, due to model limitations. For example, the cost per QALY might be less than our lower bound estimate of $137,900 had our model allowed for vaccine protection against re-infection. Models that specifically incorporate men who have sex with men (MSM) are needed to provide a more comprehensive assessment of male HPV vaccination strategies.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Harrell W. Chesson, Elissa Meites, Donatus U. Ekwueme, Mona Saraiya, Lauri E. Markowitz,